Tag Archives: contrast-agents

Ex vivo method to evaluate MRI contrast agents

“A 2014_coverJnanobiotechnologynew ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study” by Candiota A.P., Acosta M., Simões R.V., Delgado-Goñi T., Lope-Piedrafita S., Irure A., Marradi M., Bomatí-Miguel O., Miguel-Sancho N., Abasolo I., Schwartz S. Jr., Santamaría J., Penadés S., Arús C. J Nanobiotechnology 2014 12:12. DOI: 10.1186/1477-3155-12-12.

A new method has been developed for selecting MRI contrast agents with better expected in vivo performance. This method requires only a very small amount of contrast agent (e.g. 5 nmols/animal, 800 times less than the quantity necessary for in vivo administration) and allows to carry out a more rationally informed candidate selection, avoiding unnecessary in vivo and toxicology tests for the ex vivo poorly performing substances, consequently reducing animal needs, material consumption and overall costs. Continue reading Ex vivo method to evaluate MRI contrast agents

DMSO as a magnetic resonance contrast agent for brain tumors

“Dimethyl sulfoxide (DMSO) as a potential contrast agent for brain tumors”, by Delgado-Goñi T, Martín-Sitjar J, Simões RV, Acosta M, Lope-Piedrafita S, Arús C.; NMR in Biomedicine. 2012.
DOI: 10.1002/nbm.2832
.

Identifying the type of brain tumor helps doctors determine the most appropriate course of treatment. Brain tumor diagnosis usually involves a neurological examination, brain scans, and/or an analysis of the brain tissue. Nowadays, the biopsy, although it is a very invasive procedure, is the most accurate method of obtaining a diagnosis. Continue reading DMSO as a magnetic resonance contrast agent for brain tumors

Novel MRI contrast agents: peptide-SPION conjugates

Journal Cover:Chem. Commun., 2012, 48, 5322-5324“Efficient γ-amino-proline-derived cell penetrating peptide-superparamagnetic iron oxide nanoparticle conjugates via aniline-catalyzed oxime chemistry as bimodal imaging nanoagents”, by Cavalli S, Carbajo D, Acosta M, Lope-Piedrafita S, Candiota AP, Arús C, Royo M, Albericio F; Chem. Commun 48 (2012) p. 5322. DOI: 10.1039/C2CC17937G

Recent advances in nanotechnology have offered new opportunities for detection, prevention, and treatment of different diseases. In this respect engineered superparamagnetic iron oxide nanoparticles (SPIONs) represent an advanced tool in nanomedicine because they can be loaded in a multiple and orthogonal way with drugs and probes in order to simultaneously act as molecular imaging agents and drug carriers. Continue reading Novel MRI contrast agents: peptide-SPION conjugates